<DOC>
	<DOCNO>NCT00543023</DOCNO>
	<brief_summary>To compare effect treatment teriparatide salmon calcitonin postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Study Treatment Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Ambulatory , postmenopausal woman age 5585 year ( least 3 year elapse menopausal ) include time entry trial . They free severe chronically disable condition osteoporosis . The patient document ( Xray ) prevalent osteoporotic vertebral fracture nonvertebral fragility fracture ( exclude major trauma ) . Vertebral deformity evaluate lateral view thoracic lumbar spine . T12 visible view vertebrae T4 L4 identify . The radiograph perform accord standardize protocol . L1 L4 vertebra must without artifact , multiple vertebral fracture ; therefore least 3 vertebra without fracture , osteophyte , abnormality would interfere analysis posterioranterior lumbar spine BMD measurement . The reading BMD , Tscore range 2.0 4.0 least one 2 site measure ( spine hip ) . The initial lumbar spine femoral neck BMD assessment determination patient 's eligibility entry screen phase make central quality assurance BMD . The central quality assurance center determine patient 's eligibility enrollment treatment phase . If L1 vertebra analyze due artifact , vertebral fracture , osteophytes , abnormality , vertebra exclude analysis . Women without language barrier , cooperative expect return followup procedure give informed consent enter study inform risk , medication , procedure use study . Normal clinically insignificant abnormal laboratory value include serum calcium , PTH ( 184 ) level alkaline phosphatase . History sprue , inflammatory bowel disease , malabsorption syndrome 1 year prior Visit 2 . History nephrolithiasis urolithiasis 2 year prior Visit 2 . Patients history nephro urolithiasis must appropriate radiology study within 6 month prior Visit 2 . This radiology study , intravenous pyelogram supine radiograph kidneyureterbladder , must document absence active disease . History malignant neoplasms 5 year prior screen , exception superficial basal cell carcinoma squamous cell carcinoma skin definitively treat . Patients carcinoma situ uterine cervix treat definitively 1 year prior entry study may enter study . Patients increase baseline risk osteosarcoma : Paget 's disease bone unexplained elevation alkaline phosphatase ; patient receive radiation therapy involve skeleton . History diseases affect bone metabolism postmenopausal osteoporosis Paget 's disease , renal osteodystrophy , osteomalacia , secondary cause osteoporosis , hypoparathyroidism , hyperparathyroidism , hyperthyroidism .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>